Ansu Satpathy
@Satpathology
immunotherapy, genomics, data, cancer @Stanford @Wing_VC @GladstoneInst @CartographyBio @Immunaitech @joinprox @parkerici
Atul Butte died yesterday. The world lost a giant. A big bear of a man. With a huge smile. With love for everyone. With energy that could power a room. I loved everything about Atul. I loved how he was always happy. I loved how excited he was about science and helping people.
I am a strong believer that depth of data can be just as powerful as scale of data. Deep analysis of small groups of humans, and even individuals, can lead to novel biological insights and principles. Today I am the guinea pig. In my own blood, @CalebLareau finds strong evidence…
T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too? That’s the question @yile_dai looked to answer in his thesis work, out today in @Nature! 🧵below nature.com/articles/s4158…
this is such an interesting paper - suggests that the immune system may be a major (and tractable) target for aging intervention. the brain - immune interaction is also interesting, given findings from several groups that have shown replacement of brain microglia by peripheral…
I'm thrilled to share our new study out in @NatureMedicine! We show that a blood test can estimate how aged or youthful one’s organs are and that these organ ages predict future disease and lifespan. Final paper from my PhD in the @wysscoray lab. 🧵1/12 🔗 nature.com/articles/s4159…
🌟 Meet the 2025 Lloyd J. Old STARs- five extraordinary rising scientific leaders whose work is pushing the boundaries of what’s possible in cancer immunotherapy! Discover: bit.ly/4kFIjmo #CancerResearch #Immunotherapy (1/2)
🚨 New Preprint 🚨 A continuous landscape of signaling encodes a corresponding landscape of CAR T cell phenotype How can we tune JAK/STAT signaling to create better immune cell therapies? doi.org/10.1101/2025.0…
The general public would think we’re absolutely nuts… derisking is one thing but this is ridiculous $xbi
Awesome to have @JSheltzer at Stanford!
I’m thrilled to share that I’m joining the faculty at the Stanford University School of Medicine. My lab and I will be relocating to Stanford this summer!
About a year ago I thought how it must be nice to be building a company working with known tx modality going after known targets. Now I think that the only way to win in biotech is to be building anything but that.
We are pleased to share our work evaluating some of the latest single-cell platforms, including updated chemistries, in two separate experiments using peripheral blood mononuclear cells (PBMCs). biorxiv.org/cgi/content/sh…
Solving the "replication crisis" is dumb because (1) it's not a crisis, (2) the medicine is worse than the disease. Much of this is because people want science to be more like engineering, and it's not. It's fundamentally different and trying to treat engineering processes like…
If antigen expression is tightly restricted and tumor-specific, like KLK2 versus PSMA, then unmasked TCEs could offer a better therapeutic index without the risk of premature systemic activation.
awesome clone tracing method and story from @AlejoFraticelli and colleagues
Absolutely thrilled to share with you the final version of EPIclone, out now (open access) in @Nature. This has been an amazing collaboration with the lab of Lars Velten (@larsplus) at @CRGenomica nature.com/articles/s4158…
Absolutely thrilled to share with you the final version of EPIclone, out now (open access) in @Nature. This has been an amazing collaboration with the lab of Lars Velten (@larsplus) at @CRGenomica nature.com/articles/s4158…
I once quit a study section mid-review because a reviewer gave an exceptionally productive physician-scientist trainee (after 15 years of training) a non-fundable K08 score because of small deficiencies in their animal protocol. He said he was being 'fair.' I yelled at him and…
The NIH is broken. Much of $50 billion a year funds bureaucracy, political nonsense, and academic welfare instead of breakthrough science. America needs to slash the red tape, fund bold ideas, and stop rewarding mediocrity if we want to lead the next golden age of science. 🧵
congratulations to @jacobkimmel @byersblake and team - great to see people driving hard towards innovative medicines!
We’ve raised a $130 million Series B led by @kleinerperkins alongside new investors @natfriedman/@danielgross , @vkhosla, and @humancapital — joined by existing investors @foundersfund , @_DimensionCap, and @brian_armstrong (yes, the cofounders are doubling down). We also raised…
really cool
Just a few months ago, the Baker and Garcia labs released con-concurrent preprints with incredible results. They designed de novo miniproteins that bound specific peptides presented in MHC-I. Now let me show how you can use BindCraft at @AriaxBio to do the same thing.
great perspective from @AlexKolicich
My Q1 2025 State of Venture Update is out—focusing on China’s rapid rise in AI, biotech, defense, and more. The latest update explores the economic and startup implications, including Trump’s tariffs and China’s tech ascendancy. Read more: alexkolicich.com/p/q1-2025-stat…
so cool to see 3 of my favorite teams working together! @parkerici @Immunaitech @10xGenomics
Thrilled to kick off this important collaboration. @Immunaitech and the @parkerici Collaborate to Build One of the Largest Single-Cell Datasets in Cancer #scRNAseq #realworlddata search.app/aGdAhWRA7QzoGY…